WO2024127214 - A NOVEL SMALL MOLECULE KRAS INHIBITOR: DRUGGING UNDRUGGABLE TARGETS FOR CANCER THERAPEUTICS
National phase entry:
Publication Number
WO/2024/127214
Publication Date
20.06.2024
International Application No.
PCT/IB2023/062486
International Filing Date
11.12.2023
Title **
[English]
A NOVEL SMALL MOLECULE KRAS INHIBITOR: DRUGGING UNDRUGGABLE TARGETS FOR CANCER THERAPEUTICS
[French]
NOUVEL INHIBITEUR DE KRAS À PETITES MOLÉCULES CIBLANT DES CIBLES NON TRAITABLES POUR THÉRAPIES ANTI-CANCÉREUSES
Applicants **
PILLAI UNIVERSAL LLC
Inventors
M.G., Dinesh
PILLAI, Baskaran
Priority Data
202241072448
15.12.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2000 | |
| EPO | Filing, Examination, Granting | 11576 | |
| Japan | Filing, Examination, Granting | 2031 | |
| South Korea | Filing, Examination, Granting | 1871 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,218
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention discloses a anticancer activity exhibiting compound of structural formula I : Formula I or a pharmaceutically acceptable salt thereof; in which ▪ W is selected from a group comprising of substituted saturated/unsaturated branched/linear aliphatic amine, substituted aromatic amine, unsubstituted saturated/unsaturated branched/linear aliphatic amine, unsubstituted aromatic amine; ▪ X is selected from a group comprising of H, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkyl group with atleast one carbon atom, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkoxy group with atleast one carbon atom, substituted/unsubstituted aryl group, substituted/unsubstituted aryloxy group; ▪ Y is selected from a group comprising of H, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkyl group bonded to a carbonyl group, substituted/unsubstituted aryl group bonded to a carbonyl group; ▪ Z is selected from a group comprising of H, OH.[French]
La présente invention concerne un composé ayant une activité anticancéreuse de formule développée I : Formule I, ou un sel pharmaceutiquement acceptable de celui-ci ; dans laquelle ▪ W est choisi dans un groupe comprenant une amine aliphatique ramifiée/linéaire saturée/insaturée substituée, une amine aromatique substituée, une amine aliphatique ramifiée/linéaire saturée/insaturée non substituée, une amine aromatique non substituée ; ▪ X est choisi dans un groupe comprenant H, un groupe alkyle aliphatique ramifié/linéaire saturé/insaturé substitué/non substitué ayant au moins un atome de carbone, un groupe alcoxy aliphatique ramifié/linéaire saturé/insaturé substitué/non substitué ayant au moins un atome de carbone, un groupe aryle substitué/non substitué, un groupe aryloxy substitué/non substitué ; ▪ Y est choisi dans un groupe comprenant H, un groupe alkyle aliphatique ramifié/linéaire saturé/insaturé substitué/non substitué lié à un groupe carbonyle, un groupe aryle substitué/non substitué lié à un groupe carbonyle ; ▪ Z est choisi dans un groupe comprenant H, OH.